When is intermittent androgen deprivation therapy an option in advanced prostate cancer?

Speaker: Dr. Nicholas Power
Original Date: Tuesday October 13, 2015

Join Dr. Nicholas Power as he presents "When is intermittent androgen deprivation therapy an option in advanced prostate cancer?"
During this webinar, you'll learn about:

  • Understand the rationale for intermittent androgen deprivation therapy(IADT) in men with advanced prostate cancer
  • Determine which men should/should not be considered for IADT
  • Describe prognostic factors in patients undergoing IADT
  • Discuss a practical approach to the use of IADT in clinical practice

Speaker – Dr. Nicholas Power

Dr. Nicholas Power completed his undergraduate training at the University of New Brunswick, Fredericton, NB and the University of Bristol, England where he obtained his Bachelor of Science degree focusing on medical genetics, clinical pharmacology and biochemistry. He went on to complete medical school and urology residency at Dalhousie University, and became a Fellow of the Royal College of Surgeons of Canada in 2009. He subsequently completed a urologic oncology fellowship at Memorial Sloan-Kettering Cancer in New York where he trained with many of the world’s leading urology cancer specialists. He completed clinical and translational research focusing on kidney, prostate, and urothelial cancers. He trained in robotic, laparoscopic and open techniques of managing urologic malignancies while in New York.

Dr. Power has presented at national and international urology meetings and has coauthored several peer reviewed research articles. His current clinical focus is on the multimodal treatment of kidney and testis cancer. His research interests include both clinical and translational investigation in the field of urologic oncology. Dr. Power is an assistant professor at the University of Western Ontario and is based out of Victoria Hospital.

About Expert Angle

Expert AngleExpert Angle is designed to expand our reach and address the many varied and complex questions that come with a prostate cancer diagnosis. These webinars will address topics important to men with prostate cancer along different points of the cancer care continuum and those within their circle of care as well as the general public and representatives from the clinical community.
The meetings are hosted using interactive on-line technology and feature leading experts in prostate cancer - making them accessible to anyone, regardless of their location, within Canada. The platform allows PCC to communicate directly with individuals in a variety of settings (i.e. in their homes, support group meetings, community centres) and geographic locations (i.e. urban, rural and remote locations) as well as measure engagement.   

View more Expert Angle webinars.


Donate Now!

Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.

Prostate Cancer Canada launches first national program in radioligand therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.

Click here for news archive